Arterial stiffness represents a hallmark of vascular aging and is increasingly recognized as an independent predictor of cardiovascular morbidity and mortality in the elderly. This review synthesizes contemporary evidence on the pathophysiological remodeling of arterial stiffness with advancing age, elucidates epidemiological data, risk factors, clinical manifestations, diagnostic modalities, and provides a critical appraisal of current and emerging therapeutic strategies. Special emphasis is placed on clinical relevance for healthcare professionals, integrating recent guideline recommendations and addressing practical implications for patient management in geriatric populations.
With the global demographic shift towards an aging population, age-associated cardiovascular changes demand heightened clinical attention. Among these, arterial stiffness, characterized by reduced arterial compliance and increased pulse wave velocity (PWV), is a pivotal process that underpins a spectrum of cardiovascular diseases. Understanding the mechanisms and clinical significance of arterial stiffness remodeling in advanced age is essential for optimizing patient outcomes and tailoring individualized management strategies.
Arterial stiffness prevalence escalates with age, affecting over 70% of individuals above 70 years. Epidemiological studies, including the Framingham Heart Study and Multi-Ethnic Study of Atherosclerosis (MESA), consistently demonstrate a robust association between elevated arterial stiffness and incident hypertension, heart failure, stroke, and all-cause mortality. The global burden is accentuated by increasing longevity, resulting in a growing population at risk for adverse cardiovascular events attributable to vascular stiffening. Notably, the interplay of comorbidities such as diabetes, chronic kidney disease, and metabolic syndrome further amplifies disease burden among older adults.
Arterial stiffness remodeling in advanced age is driven by a complex interplay of structural and functional changes within the vascular wall. Key mechanisms include fragmentation and degeneration of elastin fibers, increased collagen deposition, cross-linking via advanced glycation end products (AGEs), and chronic low-grade inflammation. Endothelial dysfunction, oxidative stress, vascular smooth muscle cell (VSMC) phenotypic switching, and calcification contribute to the progressive loss of arterial elasticity. The resultant increase in systolic blood pressure and pulse pressure propagates end-organ damage, perpetuating a deleterious feedback loop.
While chronological aging is the predominant risk factor, several modifiable and non-modifiable determinants accelerate arterial stiffening. These include hypertension, dyslipidemia, obesity, diabetes mellitus, sedentary lifestyle, smoking, and genetic predisposition. Chronic kidney disease and chronic inflammatory states further potentiate vascular remodeling. Hormonal alterations, particularly the decline in estrogen post-menopause, are implicated in heightened arterial stiffness among elderly women.
Arterial stiffness itself is often clinically silent but significantly modulates hemodynamics, leading to isolated systolic hypertension, widened pulse pressure, and increased left ventricular afterload. This manifests as exertional dyspnea, reduced exercise tolerance, and progression to heart failure with preserved ejection fraction (HFpEF). Additionally, microvascular damage increases the risk of cognitive impairment, chronic kidney disease, and stroke in geriatric patients. The clinical sequelae underscore the importance of early identification and intervention.
Pulse wave velocity (PWV), particularly carotid-femoral PWV, is the gold standard for non-invasive assessment of arterial stiffness and is strongly correlated with adverse cardiovascular outcomes. Other modalities include augmentation index (AIx), oscillometric pulse wave analysis, and imaging-based measures such as MRI and ultrasound-derived arterial distensibility. Incorporating arterial stiffness evaluation into routine cardiovascular risk stratification enhances prognostication, particularly in older adults with multiple comorbidities.
Management of arterial stiffness centers on aggressive modification of cardiovascular risk factors. Antihypertensive agents, notably renin-angiotensin system inhibitors (ACE inhibitors, ARBs), calcium channel blockers, and mineralocorticoid receptor antagonists, have demonstrated efficacy in reducing arterial stiffness. Statin therapy and glycemic control are beneficial in patients with dyslipidemia and diabetes, respectively. Lifestyle interventions including regular aerobic exercise, dietary modification (DASH or Mediterranean diets), smoking cessation, and weight management are cornerstone strategies. Pharmacological interventions are most effective when integrated with sustained lifestyle changes and tailored to individual risk profiles.
Novel therapeutic avenues are under investigation to directly target vascular remodeling. Advanced glycation end product (AGE) breakers, endothelin receptor antagonists, and agents modulating matrix metalloproteinases show promise in preclinical studies. SGLT2 inhibitors, initially developed for glycemic control, have demonstrated vascular benefits and improved arterial compliance in clinical trials. Emerging data supports the role of anti-inflammatory therapies and senolytic agents in mitigating age-related vascular changes. Non-pharmacological interventions such as high-intensity interval training and resistance exercise regimens are also gaining traction for their impact on vascular health in the elderly.
Current guidelines from the European Society of Cardiology (ESC) and American Heart Association (AHA) advocate for routine assessment and management of arterial stiffness, particularly in older adults at high cardiovascular risk. Blood pressure control remains paramount, with individualized targets based on frailty, comorbidities, and patient preferences. Incorporating non-invasive arterial stiffness measurements can refine risk stratification and therapeutic decisions. Multidisciplinary approaches, integrating primary care, geriatrics, and cardiology, are recommended to optimize vascular health in advanced age.
Arterial stiffness remodeling in advanced age is a multifaceted process with profound clinical implications. Early detection, comprehensive risk factor modification, and integration of emerging therapies hold promise for mitigating cardiovascular risk and improving quality of life in the elderly. Ongoing research into the molecular underpinnings and novel interventions will further refine strategies for prevention and management, underscoring the need for continued vigilance and innovation in the care of aging populations.
1.
Stem Cell Selection Unneeded for SSc Transplant Therapy?
2.
Radiation from CT scans could account for 5% of all cancer cases a year, study suggests
3.
Do I have prostate cancer? Why a simple PSA blood test alone won't give you the answer
4.
In Hemophilia A and B, a Novel Monoclonal Antibody Reduces Bleeding.
5.
Tumor infiltration of major blood vessels, not metastasis, may be primary cause of cancer death
1.
Revolutionizing Oncology Trials: Optimization, Matching, Diversity, and Decentralization
2.
Emerging Dysregulated Signaling Pathways in Early-Onset Colorectal Cancer
3.
Exploring the Use of Bevacizumab in Treating Different Types of Cancers
4.
A Closer Look at Poorly Differentiated Carcinoma: Uncovering its Complexities
5.
Unlocking the Secrets of Squamous Cell Carcinoma: New Hope for Patients
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
INO-VATE: The Long-Term Overall Survival Analysis in Iontuzumab-Treated Patients
2.
The Era of Targeted Therapies for ALK+ NSCLC: A Paradigm Shift
3.
A New Era in Managing Cancer-Associated Thrombosis
4.
Navigating the Complexities of Ph Negative ALL - Part IX
5.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VIII
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation